← Back to patent-cliff list
ODN/Pam2
Tier C — Watch / tradeODN/Pam2
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TLR6, TLR9, TLR2
Indications (approved)：Haematological malignancy, COVID-19, Chronic obstructive pulmonary disease
Regional status
US
Phase II
2020-06-09
EU
No progress
2019-01-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ODN/Pam2?
Approved indications include: Haematological malignancy, COVID-19, Chronic obstructive pulmonary disease.
When does the ODN/Pam2 patent expire?
No public expiry year is available for ODN/Pam2 yet; this page updates once verified.
How do I get a quote for ODN/Pam2 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08